Mitsubishi Tanabe Pharma updates license agreement with Kolon Life Secience on Invossa
Dec 20 (Reuters) - Mitsubishi Tanabe Pharma Corp <4508.T>:Says it notified Kolon Life Secience, Inc. (KLS) that the co seeks to cancel the license agreement between the co and KLS for Invossa, a cell therapy product for improvement of knee osteoarthritis symptoms .Says it has started negotiation with KLS regarding the cancellation of the License Agreement .
Latest Developments forMitsubishi Tanabe Pharma Corp
Latest Key Developments inPharmaceuticals
- Creso Pharma Requests A Trading Halt Pending An Announcement
- ECS Botanics Says Co Will Execute Call Option To Acquire Tasmanian Hemp Farm
- Genmab: Partner For Ofatumumab Presents Positive Results From Phase III Asclepios I, II Studies
- Orchard Therapeutics Announces Departure Of Chief Commercial Officer